Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France

• Franck Maunoury ,

  Contributed equally to this work with: Franck Maunoury, Chizoba Nwankwo

  Roles Conceptualization, Formal analysis, Funding acquisition, Methodology, Writing – original draft, Writing – review & editing

  * E-mail: franck.maunoury@statesia.com

  Affiliation Statesia, Le Mans, France

  http://orcid.org/0000-0003-1045-4666

  ⨯
• Aurore Clément,

  Roles Data curation, Project administration, Resources, Supervision, Visualization

  Affiliation MSD FRANCE, Paris, France

  ⨯
• Chizoba Nwankwo ,

  Contributed equally to this work with: Franck Maunoury, Chizoba Nwankwo

  Roles Conceptualization, Formal analysis, Methodology, Project administration, Software, Visualization, Writing – review & editing

  Affiliation Merck & Co., Inc., Kenilworth, New Jersey, United States of America

  ⨯
• Laurie Levy-Bachelot,

  Roles Project administration, Visualization, Writing – review & editing

  Affiliation MSD FRANCE, Paris, France

  ⨯
• Armand Abergel,

  Roles Writing – review & editing

  Affiliation Hepato-gastro enterology Service, CHU Estaing, Clermont-Ferrand, France

  ⨯
• Vincent Di Martino,

  Roles Writing – review & editing

  Affiliation Hepatology Department, Franche-Comté University and Besançon University hospital, Besançon, France

  ⨯
• Eric Thervet,

  Roles Writing – review & editing

  Affiliations HYPPARC Department, Nephrology Service, Paris Descartes University, Paris, France, Georges Pompidou European Hospital (ET), Paris, France

  ⨯
• Isabelle Durand-Zaleski

  Roles Writing – review & editing

  Affiliation Ile-De-France URC ECO, Department of Public Health, Henri Mondor Hospital, Créteil, France

  ⨯